QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • MediciNova, Inc. (MNOV) Receives Notice Of European Patent Allowance For MS Drug 0 comments
    Nov 26, 2012 10:39 AM | about stocks: MNOV

    MediciNova received a notice of allowance from the European Patent Office for a pending patent application which covers the use of ibudilast (MN-166) for the treatment of progressive forms of multiple sclerosis (NYSE:MS). MN-166 is the company's drug development candidate for certain neurological conditions, including progressive MS, drug addiction, and pain. Patents maturing in this type of application are not expected to mature before 2029 and will cover multiple methods of treating primary or secondary progressive MS.

    "Treatment options for patients who have progressive MS are very limited and assessing potential pharmacotherapies like ibudilast may offer real hope," said Dr. Frederik Barkhof, professor of neuroradiology and medicine, VU Medical Center, Amsterdam.

    The patent application is based upon clinical investigations conducted by MediciNova and collaborating researchers that showed adisease-modifying benefit. The benefit identified is that brain volume loss (brain atrophy) commonly associated with disease progression was demonstrated to be reduced by oral administration of ibudilast to a group of MS patients in a dose-related fashion over at least a 10-month treatment period. Ibudilast has been used in asthma and post-stroke disorders in Japan for about 20 years. MediciNova has demonstrated the potential utility of ibudilast in the treatment of neurological disorders at higher doses with encouraging outcomes in company-sponsored clinical trials in multiple sclerosis (MS) and neuropathic pain.

    "We are very pleased with this positive step in our patent portfolio, It complements our strategy to advance MN-166 into Phase II proof-of-concept clinical development for progressive multiple sclerosis," said Yuichi Iwaki, president and CEO of MediciNova.

    MediciNova is a biopharmaceutical company that acquires and develops small-molecule therapeutics for the treatment of diseases. MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorder, preterm labor, and urinary incontinence, as well as two preclinical-stage compounds for the treatment of thrombotic disorders.

    For more information on MediciNova, visit medicinova.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: MNOV
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.